Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs

Salim S. Virani; Julia M. Akeroyd; Vijay Nambi; Paul A. Heidenreich; Pamela B. Morris; Khurram Nasir; Erin D. Michos; Vera A. Bittner; Laura A. Petersen; Christie M. Ballantyne

doi:10.1161/CIRCULATIONAHA.117.028503

Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs

Salim S. Virani, Julia M. Akeroyd, Vijay Nambi, Paul A. Heidenreich, Pamela B. Morris, Khurram Nasir, Erin D. Michos, Vera A. Bittner, Laura A. Petersen, Christie M. Ballantyne

Research output: Contribution to journal › Letter › peer-review

56 Citations (Scopus)

Original language	English
Pages (from-to)	2572-2574
Number of pages	3
Journal	Circulation
Volume	135
Issue number	25
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.117.028503
Publication status	Published - 20 Jun 2017
Externally published	Yes

Keywords

cardiovascular disease
cholesterol
lipids

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1161/CIRCULATIONAHA.117.028503

Cite this

Virani, S. S., Akeroyd, J. M., Nambi, V., Heidenreich, P. A., Morris, P. B., Nasir, K., Michos, E. D., Bittner, V. A., Petersen, L. A., & Ballantyne, C. M. (2017). Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs. Circulation, 135(25), 2572-2574. https://doi.org/10.1161/CIRCULATIONAHA.117.028503

Virani, Salim S. ; Akeroyd, Julia M. ; Nambi, Vijay et al. / Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) : Insights from the Department of Veterans Affairs. In: Circulation. 2017 ; Vol. 135, No. 25. pp. 2572-2574.

@article{a452017e3f7644c7b99dc07508b5e289,

title = "Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs",

keywords = "cardiovascular disease, cholesterol, lipids",

author = "Virani, {Salim S.} and Akeroyd, {Julia M.} and Vijay Nambi and Heidenreich, {Paul A.} and Morris, {Pamela B.} and Khurram Nasir and Michos, {Erin D.} and Bittner, {Vera A.} and Petersen, {Laura A.} and Ballantyne, {Christie M.}",

year = "2017",

month = jun,

day = "20",

doi = "10.1161/CIRCULATIONAHA.117.028503",

language = "English",

volume = "135",

pages = "2572--2574",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "25",

}

Virani, SS, Akeroyd, JM, Nambi, V, Heidenreich, PA, Morris, PB, Nasir, K, Michos, ED, Bittner, VA, Petersen, LA & Ballantyne, CM 2017, 'Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs', Circulation, vol. 135, no. 25, pp. 2572-2574. https://doi.org/10.1161/CIRCULATIONAHA.117.028503

Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs. / Virani, Salim S.; Akeroyd, Julia M.; Nambi, Vijay et al.
In: Circulation, Vol. 135, No. 25, 20.06.2017, p. 2572-2574.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk)

T2 - Insights from the Department of Veterans Affairs

AU - Virani, Salim S.

AU - Akeroyd, Julia M.

AU - Nambi, Vijay

AU - Heidenreich, Paul A.

AU - Morris, Pamela B.

AU - Nasir, Khurram

AU - Michos, Erin D.

AU - Bittner, Vera A.

AU - Petersen, Laura A.

AU - Ballantyne, Christie M.

PY - 2017/6/20

Y1 - 2017/6/20

KW - cardiovascular disease

KW - cholesterol

KW - lipids

UR - http://www.scopus.com/inward/record.url?scp=85020903486&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.117.028503

DO - 10.1161/CIRCULATIONAHA.117.028503

M3 - Letter

C2 - 28465286

AN - SCOPUS:85020903486

SN - 0009-7322

VL - 135

SP - 2572

EP - 2574

JO - Circulation

JF - Circulation

IS - 25

ER -

Virani SS, Akeroyd JM, Nambi V, Heidenreich PA, Morris PB, Nasir K et al. Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs. Circulation. 2017 Jun 20;135(25):2572-2574. doi: 10.1161/CIRCULATIONAHA.117.028503

Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): Insights from the Department of Veterans Affairs

Keywords

UN SDGs

Access to Document

Other files and links

Cite this